, and Gary S. Marshall, MD 12 I n the last 20 years, autoinflammatory syndromes, a new category of immune-mediated diseases, have been described. These diseases are defined as attacks of inflammation, often multisystem, that are unprovoked (or triggered by a minor event) and primarily are related to dysregulation of the innate immune system. 1 Many of the syndromes are monogenically inherited. Unlike autoimmune diseases, there is a relative deficiency of both autoantibodies and autoreactive T lymphocytes. The inflammatory response is usually mediated by proinflammatory cytokines, especially interleukin (IL)-1 secreted by granulocytes and monocytes. These syndromes are often classified by the major mechanism of the immune dysfunction ( Table I) .
Autoinflammatory diseases should be suspected in patients with recurrent fever and increased acute phase reactants not explained by infections and/or when episodes are accompanied by stereotypic episodic symptoms in various body systems. Often a suggestive family history is elicited in monogenically inherited conditions including features of earlyonset hearing loss, amyloidosis and/or renal failure.
Periodic/recurrent fever syndromes were the former name for these diseases. However, fever is neither necessary nor recurrent in some of the syndromes. Only in the periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA)-perhaps the most common autoinflammatory condition in children-are febrile episodes truly periodic. This report summarizes information presented at the First International Symposium on PFAPA, which took place at Schneider Children's Medical Center of Israel on June 2, 2016. The symposium focused on our current understanding of the clinical, diagnostic, pathogenic, and treatment aspects of PFAPA and the challenges and future research necessary to increase our knowledge of this unique syndrome.
PFAPA Syndrome in the Context of Unexplained Fevers in Children
Fever is the endogenous elevation of core body temperature. 2 The classic papers addressing fever of unknown origin in children used minimum temperatures ranging from 38.1°C to 38.9°C (100.5°F to 102.1°F) to define "fever," with no uniformity in method or site of measurement. [2] [3] [4] [5] [6] [7] Operationally, it seems reasonable to consider a core body temperature of ≥38.0°C (100.4°F) as abnormal. The most accurate measurements are obtained using liquid-in-glass or thermistor-based electronic thermometers that come into direct contact with the patient. 8 From birth through 3 years of age, the device is usually placed in the rectum; at ≥5 years of age, it is usually placed in the sublingual space. Between 3 and 5 years of age, placement in the axilla is more feasible, and the addition of 0.6°C
FMF
Familial Mediterranean fever IL Interleukin PFAPA Periodic fever, aphthous stomatitis, pharyngitis, adenitis (1.0°F) to the reading can be used to approximate core temperature. 9 Undifferentiated fever occurs when fever is the main complaint and is unaccompanied by clinical features that suggest an etiology (this is not the same as fever without source, which refers to young febrile children who are at risk for acute serious bacterial infection). 10 Undifferentiated fevers in previously healthy children can be classified as follows: (1) prolongedlasting longer than expected for a common illness, (2) intermittent-unpredictable, lasting for days to weeks and occurring more commonly than expected for a healthy child, or (3) periodic-stereotypical episodes lasting for several days recurring with clockwork periodicity over years. Although patients with prolonged fever may have infectious, inflammatory, neoplastic, or a host of miscellaneous conditions, the majority who are referred to infectious diseases specialists never receive a specific diagnosis and their fevers eventually resolve.
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This may be due to the fact that the more ominous diagnoses are made in the periphery, and that referral occurs only after readily available diagnostic options have been exhausted. In evaluating the well-appearing child with prolonged fever, the cadence of the illness should dictate the pace of evaluation. 12 Steps include carefully cataloging symptoms, fever pattern, physical findings, and diagnostic studies; obtaining basic screening tests (eg, complete blood count, peripheral blood smear, chemistries, erythrocyte sedimentation rate, C-reactive protein, urinalysis, a chest radiograph); having the patient maintain a fever diary using an accurate thermometer; and returning to the healthcare provider weekly for serial examinations and laboratory studies. 13 This approach continues until a diagnosis is made or the fever resolves.
By far the most common cause of intermittent fevers is sequential viral illnesses. Some children can have as many as 1 illness a month, 14 prompting concern that a serious underlying condition exists. Reassurance can be gained by seeking information that separates the illnesses into distinct clinicopathologic entities-for example, if 1 illness included a sore throat, the next a slight cough, and another diarrhea, the case is made that these were likely unrelated uncomplicated infections. More serious or unusual illnesses should prompt consideration of evaluation for immune deficiency. Monogenic autoinflammatory diseases are rare, but should be considered if there is a strong family history or characteristic clinical features.
The hallmark feature of periodic fever is the recurrence of symptoms at regular intervals. In cyclic neutropenia, the periodicity is a remarkably consistent 21 days. 15 Episodes of illness are preceded by a decrease in neutrophil count and are accompanied by malaise, mouth ulcers, gingivitis, periodontitis, and bacterial infections. By the time medical attention is sought, the neutrophil count may have recovered. The syndrome is caused by mutations in the neutrophil elastase gene, but the mechanism by which the neutrophil count cycles so precisely is not known.
PFAPA is the only other truly periodic fever syndrome in children. Although diagnostic criteria differ (Table II) and there is no consensus research definition, [16] [17] [18] patients with classic PFAPA are not difficult to recognize. They typically are young and have been followed by primary care providers for months to years, being given serial diagnoses of viral illness and having had negative point-of-care diagnostic tests. Parents volunteer that each episode is identical, from the clingy, glassyeyed, whiny prodrome to the abrupt onset of high fever and the sudden cessation of fever 3 or 4 days later. There is a distinct absence of other symptoms such as cough, vomiting, and diarrhea, and no other family members are ill at the same time. Aphthous stomatitis, pharyngitis, and/or (cervical) lymphadenitis, if present, support the diagnosis, and the absence of all 3 symptoms calls the diagnosis into question. Acute phase reactants are elevated during episodes and normal between episodes; if a corticosteroid is given-even a single dose of 1 mg/ kg of prednisone-the episode resolves dramatically in a few hours. The child usually does not have a rash, joint complaints, or other symptoms that would suggest an alternative diagnosis, and although there is no family history of heritable periodic fever syndromes, the parents themselves may have had recurrent fevers or had their tonsils removed as young children. Episodes occur without provocation and are so predictable that the family can plan activities around them. Between episodes, the child is perfectly well. The literature on PFAPA has grown exponentially in the 3 decades since it was first described (Figure 1) . 19 The clinical features, natural history and epidemiology have been delineated, and surrogate markers have been assessed. 17, 18, [20] [21] [22] [23] [24] Much attention has focused on the role played by the tonsils in pathogenesis, supported by the fact that their removal usually brings an end to the episodes [25] [26] [27] [28] [29] ; this finding raises the question of whether, in fact, PFAPA is what used to be called "recurrent tonsillitis." 30 Those experienced with patients with PFAPA, however, notice differences, a primary one being that recurrent tonsillitis does not follow the calendar. Investigators have begun probing the histology, cell populations, resident inflammatory mediators, and microbiome of tonsils from patients with PFAPA for clues to etiology and pathogenesis. [31] [32] [33] [34] [35] Over the past 15 years, investigators have defined the nature of an acute inflammatory response during PFAPA episodes, identifying mediators that are either causal, epiphenomenal, or both. 34, [36] [37] [38] [39] [40] [41] [42] Finally, familial clusters in geographic regions as diverse as Europe, 43 Japan, 44 and the US 45 have been described, and whole exome sequencing suggests that PFAPA is either transmitted in Mendelian fashion with high genetic heterogeneity or as an oligogenic or complex trait. 46 Fever and inflammation have been linked together for thousands of years, as illustrated in the following passage from the Bible:
And with inflammation and with fiery heat or an extreme burning and with the sword. G-d will strike you with wasting disease, with fever and inflammation with scorching heat and drought, with blight and mildew, which will plague you until you perish. Deuteronomy 28 :22 Living in this "fiery heat" of recurrent fevers is not easy for the affected individuals with PFAPA and their families, who suffer through episodes physically, psychologically, and socially in ways that can interfere with their function and quality of life. PFAPA represents many challenges for the clinician as well, including difficulty establishing an early diagnosis, the lack of diagnostic tests for the syndrome, the absence of biomarkers that reliably distinguish PFAPA flares from other conditions associated with fever, and the paucity of data to inform evidence-based decision making and biologically grounded therapeutics. Understanding the heterogeneity of the syndrome and studying maturational aspects of the immune system that are likely intertwined with etiology will be important investigations.
IL-1 in the Pathogenesis of PFAPA
This section reviews a proposed mechanism for PFAPA based on a systems-biology approach, details the response of patients with PFAPA to IL-1 inhibition (an off-label use of medication), and outlines the "IL-1 question" in terms of how it pertains to the genetics of PFAPA.
In 1999, >10 years after PFAPA was described, Sarah Long wrote that PFAPA "walks like dysregulation of cytokines and talks like an infection." 47 The occurrence of PFAPA in young children and apparent cure after tonsillectomy suggests an infectious etiology; in contrast, responsiveness to corticosteroids suggests immune dysregulation. Additionally, the regularity and stereotypical nature of PFAPA febrile attacks suggests immune dysregulation as a potential mechanism to this autoinflammatory disorder.
A collaborative project reported by Stojanov et al was undertaken in which blood samples were taken from welldefined patients with PFAPA during attacks and during WORKSHOP/SYMPOSIUM SUMMARY asymptomatic interval periods to investigate whether there was a unique biological "signature" in patients with PFAPA compared with healthy children and patients with hereditary autoinflammatory conditions. 48 Studies included lymphocyte phenotyping by flow cytometry, serum cytokine testing, and microarray analysis with quantitative confirmation by realtime polymerase chain reaction. Forty-five patients with PFAPA who were negative for variants of the MEFV, MVK, ELA2, NLRP3, and TNFRSF1A genes were included in this study; 60% of the cohort had all 3 PFAPA-associated clinical features and the remainder had ≥2 of 3 associated features. 48 Six of the patients with PFAPA who fulfilled stringent diagnostic criteria had paired samples that were compared with healthy controls and hereditary autoinflammatory condition controls using principal component analysis. During asymptomatic intervals, patients with PFAPA segregated with healthy pediatric controls. During flares, patients with PFAPA were distinct from asymptomatic periods, and also were distinct from hereditary autoinflammatory patients during a flare (Figure 2 , A; available at www.jpeds.com). 48 The upregulation of complement and interferon-associated genes and downregulation of T-lymphocyte-associated transcripts in patients with PFAPA during a flare were significantly different from findings in patients with hereditary autoinflammatory conditions during a flare, healthy pediatric controls, and paired patients with PFAPA samples during interludes of wellness; IL-1bassociated genes also were upregulated (Figure 2, B) . Increased IL-1b expression in patients with PFAPA during flares was validated in a larger group of patients with PFAPA using RNA transcript level measurement in whole blood by quantitative real-time polymerase chain reaction in comparisons with patients with PFAPA without flare, healthy controls, and patients with hereditary periodic fever syndromes during flares (Figure 2, C) . 48 Trials of drug-induced IL-1 inhibition in 5 patients with PFAPA was associated with decreases in fever (Figure 3, A; available at www.jpeds.com), chemokines, cytokines, C-reactive protein, and peripheral blood leukocytes (Figure 3, B) .
The role of IL-1 in PFAPA was further investigated by Kolly et al, who showed elevation in peripheral blood of proinflammatory IP-10, IL-6 and caspase-1, which activates IL1b and IL-18. 39 When purified monocytes from peripheral blood mononuclear cells were stimulated with lipopolysaccharides, IL-1b and IL-1 receptor antagonists were found to be increased during PFAPA flares compared with asymptomatic intervals, and healthy controls (Figure 4 ; available at www.jpeds.com) Additionally, 25% of 57 patients with PFAPA had variants in hereditary autoinflammatory genes, 12 of them in NLRP3; these were mostly of uncertain significance. 39 Interestingly, the patients with PFAPA in this cohort had a higher rate of variants than is described in the general population, implicating a role for the inflammasome in PFAPA. It was suggested that PFAPA may be a phenotype of NLRP3-related disease or a distinct syndrome. Perko et al found that 20% of patients with PFAPA had NLRP3 variants (mostly Q703K), 8% had MEFV variants; AIM2 variants were not clinically significant. Conflicting data exist regarding the presence of variants in patients with PFAPA. [49] [50] [51] [52] [53] In an additional report, an association between PFAPA and a CARD8 variant that is unable to bind the NLRP3 inflammasome was found. 54 Decreased ability of CARD8 to bind NLRP3 is consistent with increased inflammasome activity and IL-1b production. Developing a better understanding of this overlay may further elucidate the precise mechanism through which the inflammasome influences PFAPA flares, ultimately leading to targeted therapeutic strategies.
Although the inflammatory profile in serum during PFAPA attacks has been studied, 48 it remains a mystery why pharyngitis is a frequent feature of PFAPA episodes. In 1 study, the microbiota of the tonsils removed from patients with PFAPA was significantly different from controls, implying a possible role for tonsillar microbiota in triggering inflammation in PFAPA. 35 In summary, in a well-defined genetically negative PFAPA population, gene expression profiling distinguished PFAPA flares from baseline, from expression in healthy controls, as well as in known hereditary periodic fever syndromes. These findings imply that PFAPA is a distinct nosologic entity. The increase in IL-1 during PFAPA flares demonstrated in 2 different studies suggests a purported role in PFAPA febrile attacks, as well as possible IL-1 inhibition in treating PFAPA.
Therapy and Long-Term Follow-Up of Children Diagnosed with PFAPA
In 1987, our group initially reported a syndrome of recurrent episodes of fever in 12 children. In 1989, we named the syndrome, PFAPA, and proposed diagnostic criteria (Table II) . 16, 19 In 1999, we contacted 83 of 94 families of children with PFAPA with a follow-up interval ranging from <1 month to 9.4 years (mean, 3.3) to assess outcomes and effectiveness of management strategies. Glucocorticoids were rated as highly effective in controlling symptoms and tonsillectomy or tonsillectomy and adenoidectomy was associated with remission in 70%. 17 Padeh et al reported on 28 Israeli patients with PFAPA. 20 Courses were similar to US children. Fever episodes began at age 4.2 ± 2.7 years, resolved in 4.3 ± 1.7 days, and recurred at intervals of 5.1 ± 1.3 weeks. Febrile attacks were aborted by a single dose of oral prednisone in all 15 treated patients. In 9 of 28 patients, the syndrome completely resolved after 8 ± 2.5 years, and tonsillectomy was curative in 3 of 28 patients who underwent the procedure.
In 2010, Feder and Salazar reported a series of 105 patients with PFAPA. The mean age at onset was 3.3 years of age, with the majority being less than 5 years of age. 18 The mean duration of fever episodes was 4.1 days, and the mean interval between episodes was 29.8 days. They noted pharyngitis (85%), cervical adenitis (62%), aphthous stomatitis (38%), and mild abdominal pain (41%). In 20% of the patients, the episodes resolved spontaneously after a mean of about 2.8 years, and in 63% the episodes persisted at follow-up.
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In 2014, Hofer et al described a large cohort of patients with PFAPA assembled through the Pediatric Rheumatology European Society and included individuals whose diagnosis of PFAPA was made by an experienced pediatric rheumatologist. 24 Of the 301 patients included, 90% had pharyngitis, 78% had cervical adenitis, 57% had aphthous stomatitis, and 44% had all 3 clinical features. There was a male predominance (53%), the median age disease onset was 1.7 years (range, 0.1-12.0), the median interval between fever attacks was 4 weeks (range, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] , and the median duration of the attacks was 4 days (range, 1-10). Thirty-one patients had disease onset after 5 years of age. A positive family history for recurrent fever or recurrent tonsillitis was found in 27% of patients.
In 2011, we conducted a second follow-up study of US patients, contacting 59 of the original 94 patients; follow-up ranged from 12 to 21 years. 22 Overall, 50 of the 59 patients had complete resolution of symptoms, yielding a mean illness duration of 6.3 years (95% CI, 5.4-7.3). Nine patients continued to have persistent symptoms at follow-up, for a mean duration of 18.1 years. In subjects with persistent PFAPA, the duration of the febrile episodes was reduced from a mean of 3.6 days at diagnosis to 1.8 days at follow-up (P = .01). In addition, the symptom-free interval between episodes markedly lengthened from 29 to 159 days (P < .005).
Over the past several decades, a substantial number of small case series and a few randomized clinical trials have reported on various treatments for PFAPA. Exploratory therapies have included glucocorticoids, cimetidine, colchicine, IL-1 receptor inhibition with anakinra, and tonsillectomy. Most series report prompt responses to corticosteroids. Feder and Salazar 18 reported that a corticosteroid was highly effective in aborting fever episodes, but one-half of treated patients experienced more frequent episodes after use. We reported a similar increase in febrile episodes with the use of corticosteroids. 17 Yazgan et al randomized 41 patients with PFAPA to either 2 mg/kg/day or 0.5 mg/kg/day of prednisone, showing that the lower dose was as effective as the higher dose. 55 Tasher et al found that nearly 90% of their patients with PFAPA promptly responded to a corticosteroid, but they also reported a shortening of the episodes in nearly 20% of subjects. 21 Feder initially proposed cimetidine for prevention (not therapy) of episodes in patients with PFAPA. 56 We have reported inconsistent responses to prevention with cimetidine. 17, 22, 45 Tasher et al treated 9 patients with PFAPA who were between 3.5 and 11.0 years of age with a daily dose of colchicine, 0.5-1.0 mg. 57 In 8 of the 9 treated children, the interval between episodes significantly increased (P < .006). Another group of Israeli investigators conducted a randomized, controlled study of colchicine in 18 patients with PFAPA, showing some benefit. 58 Stojanov et al treated 5 patients with PFAPA using anakinra, a recombinant IL-1 receptor antagonist. 48 All 5 patients showed a prompt clinical response. The most comprehensive randomized clinical trials for the therapy of PFAPA have been those evaluating the impact of tonsillectomy. Renko et al conducted a prospective, randomized, controlled trial in 26 children with well-defined PFAPA. 27 Six months after randomization, all 14 children in the tonsillectomy group and 6 of 12 children in the control group were free of symptoms. Tonsillectomy was performed on 5 of 6 of the patients in the control group who still had symptoms after 6 months and they also had symptom resolution. Garavello et al reported on the impact of tonsillectomy in 39 patients with PFAPA who were randomized to either adenotonsillectomy or symptomatic care and were followed clinically for 18 months. 25 The percent of subjects experiencing complete resolution was 63% in the surgery group and 5% in the control group (P < .001). Since that time, we and others have reported on the success of tonsillectomy in children with PFAPA, 17, 22, 28, 29 and the data have been summarized in a Cochrane systematic review. 59 Recently, Lantto et al found that tonsillectomy was an effective treatment not only for patients with PFAPA, but also for children suffering from regularly recurring episodes of high fever without an explanation, who were asymptomatic between episodes, but who failed to meet the classic Thomas diagnostic criteria. 60 This finding raises the possibility that the spectrum of PFAPA includes patients with fever in the absence of other signs and symptoms. The challenge in diagnosing and managing PFAPA is gaining an understanding of the pathogenic underpinnings of this disorder. Continued research efforts are needed.
Pitfalls in the Diagnosis and Management of PFAPA Syndrome
Because there is no biological or a genetic marker for PFAPA, erroneous diagnosis is common. 61 In this section, pitfalls in the diagnosis of PFAPA are discussed, mostly based on our experience with a cohort of >1000 patients with PFAPA over the last 22 years at the Edmond and Lily Safra Children Hospital, Sheba Medical Center, Israel.
Age at Onset
Several published criteria of PFAPA require that the age of diagnosis be <5 years of age. 19, 24, 62 In our cohort, 28.2% of the patients first presented after the age of 5 years, with 50 patients >18 years of age. 63 There are also series of adults with PFAPA, where the ages ranged between 18 and 56 years, although the clinical presentation is identical to the childhood PFAPA syndrome. 64, 65 Given this, using young age as a criterion for diagnosis may miss cases.
PFAPA vs Familial Mediterranean Fever
Among the auto-inflammatory diseases, PFAPA is by far the most common. In countries around the Mediterranean basin, familial Mediterranean fever (FMF) is equally prevalent. Although the clinical presentation of FMF differs considerably from that of PFAPA, there is nevertheless confusion surrounding the 2 entities. Several findings help differentiate these 2 diseases, including that (1) FMF is not a periodic disease, being characterized by completely random episodes, as opposed to PFAPA where episodes occur in regular cycles, February 2018 WORKSHOP/SYMPOSIUM SUMMARY (2) abdominal pain is common in PFAPA, but never reaches the severe nature of the peritonitis in FMF, (3) although aphthae are common in both syndromes, true pharyngitis, accompanied by cervical lymphadenopathy, is not seen in FMF, (4) FMF attacks do not respond to a single dose of glucocorticoids, (5) prophylactic colchicine treatment usually prevents fever episodes in FMF but typically not in PFAPA, and (6) arthritis, pleuritis, and erysipelas-like erythema are only seen in FMF.
MEFV variants associated with FMF are often detected in patients with recurrent fever episodes. This finding may cause concern for both parents and pediatricians. However, FMF is a clinical diagnosis, and carrying MEFV variants is not sufficient for the diagnosis of FMF. Most individuals carrying MEFV variants do not develop FMF, and many cases present later in life (50% of FMF cases have their first episode at >6 years of age, and 20% at >18 years of age). 66 It is, therefore, recommended not to test for MEFV variants in the absence of symptoms suggesting FMF. 67 In fact, we have shown that MEFV may be a modifier of PFAPA, rendering PFAPA episodes less severe. 51 Others, in smaller studies, found that carrying MEFV gene mutations did not play a major role in the constellation of PFAPA symptoms. 50, 52, 68 In areas where both FMF and PFAPA are common, one expects to find patients with both diseases concurrently. We are following 35 such patients in whom prophylactic colchicine treatment prevents FMF attacks and glucocorticoids abort PFAPA attacks.
Response to Glucocorticoids
There is disagreement as to whether a response to treatment should be included in the diagnostic criteria of a disease, although including the response to treatment as a diagnostic criterion has been used for several entities, including Sweet syndrome. 69 The most unique feature of PFAPA is that a single dose of glucocorticoid eliminates the attack within several hours. This phenomenon has not been reported consistently in other autoinflammatory diseases or other forms of pharyngitis/ tonsillitis. It is, therefore, very useful in distinguishing PFAPA episodes from other conditions, and should be considered in proposed diagnostic schemes.
Exudative Tonsillitis
Fever and pharyngitis are exceedingly common in young children, and it is often difficult to differentiate between intercurrent viral infections and PFAPA episodes. However, monthly episodes over a period of several years are never due to infections. In many cases, exudates appear only toward the end of an episode, even as late as the last day of the fever. In questionable cases, the patient should be reexamined daily during an episode.
Many physicians perform throat cultures for these patients, postponing the administration of glucocorticoids and/ or prescribing antibiotics. Streptococcal carriers are relatively common in school-age populations, representing 10%-15% of children in most studies, with carriage rates varying by study from 8% to 40%. 70 Culture for group A Streptococcus is not indicated during typical episodes in patients with PFAPA.
No Response to Glucocorticoids
Failure to respond to glucocorticoids could be due to inadequate dosing. The recommended full dose is 2 mg/kg prednisone or 0.3 mg/kg betamethasone. Many patients could respond to a lower dose, and once the treatment is successful, the dose can be tapered to the minimal dose required to control episodes. Often the fever returns more frequently (as much as 1 week apart) despite a maximal dose of glucocorticoid. The routine use of corticosteroid to abort episodes of PFAPA is not favored by all experts, because of concern for side effects associated with frequent use.
It is our practice to conclude the following: (1) Fever recurring the next day-not a PFAPA episode, (2) fever recurring within 2-4 days-the corticosteroid dose is too low, and (3) attack recurs >1 week-new episode, corticosteroid dose was not relevant.
Confusion with Hyperimmunoglobulinemia Syndrome/Mevalonate Kinase Deficiency
Hyperimmunoglobulinemia syndrome is the great mimicker of PFAPA. Pharyngitis, aphthous ulcers, and lymphadenopathy are reported to occur during attacks and can be prominent features. Hyperimmunoglobulinemia syndrome is a spectrum of diseases that can range from milder symptoms to severe. The milder end of the spectrum is characterized by recurrent episodes of unexplained fever, which can be periodic, for example, monthly attacks. Some individuals present with an abrupt onset of fever accompanied by fatigue, chills, abdominal pain, lymphadenopathy, and tonsillitis. However, patients with hyperimmunoglobulinemia syndrome often have arthritis or arthralgia, rash, nausea, diarrhea, vomiting, or hepatosplenomegaly, which are not seen in PFAPA.
Exclusion Criteria for PFAPA
To avoid a variety of misdiagnoses, we suggest that the presence of any of the following should exclude the diagnosis of PFAPA: neutropenia; cough, coryza; severe abdominal pain; significant diarrhea; rash, arthritis, or neurologic abnormalities; elevated acute phase reactants between attacks; and intermittent flares rather than a true periodic disorder.
There is a dispute in the literature whether new diagnostic criteria are needed for PFAPA. To avoid pitfalls in the diagnosis of PFAPA, the following guidance may be helpful. (1) The onset of PFAPA can be at any age. 
The Eurofever Registry
The general aim of the Eurofever Registry was to build a longitudinal international registry able to collect homogeneously demographic, genetic, clinical, and therapeutic information of patients affected with different monogenic and THE JOURNAL OF PEDIATRICS • www.jpeds.com Volume 193 multifactorial autoinflammatory diseases. To this purpose, a web-based registry was created and is available in the member area of the Pediatric Rheumatology International Trial Organization website (www.printo.it/eurofever). 71 Since January 2010, 3749 patients (children and adults) from 70 centers in 40 countries have been enrolled in the registry, including 524 patients with PFAPA. One of the most important challenges regarding PFAPA is developing specific diagnostic criteria. In contrast with inherited periodic fevers such as FMF, tumor necrosis factor receptor-associated periodic syndrome, and mevalonate kinase deficiency (also known as hyperimmunoglobulinemia syndrome), for which genetic markers exist, PFAPA can only be diagnosed by fulfilment of clinical criteria. Studies have shown low specificity for the current PFAPA diagnostic criteria when applied to populations in which different inherited fever syndromes are present. 72, 73 The availability of a large international registry collecting standardized data on all periodic fevers in different countries and from patients of different ethnicities represents a good opportunity for an exhaustive comparison of different diseases. 74 Clinical diagnostic or classification criteria for periodic fevers are developed on the basis of expert opinion or by compilation of clinical manifestations observed in patients affected by a single disease, usually in the context of a limited population or ethnic background. 17, 61, 72, [75] [76] [77] [78] [79] [80] [81] Wide overlap of the clinical features of these syndromes contributes to low performance of these diagnostic criteria when applied to patients affected by different autoinflammatory diseases. 72, 73 With the aim to overcome this limitation, new evidence-based classification criteria for inherited periodic fevers were recently proposed, 81 based on the comparison of FMF, mevalonate kinase deficiency, tumor necrosis factor receptor-associated periodic syndrome, cryopyrin-associated periodic syndromes, with PFAPA being used as a negative control. A total of 518 patients with genetically confirmed inherited periodic fever syndrome (291 FMF, 74 mevalonate kinase deficiency, 86 tumor necrosis factor receptor-associated periodic syndrome, and 67 cryopyrinassociated periodic syndrome) and 199 patients with PFAPA were included in the study. For inherited periodic fevers, only patients with a confirmatory genetic test were included. 81 PFAPA was classified according to the diagnostic criteria. 16, 17 The centers were contacted retrospectively and were asked whether, during the follow-up after the enrollment, the diagnosis of PFAPA was confirmed or if a different diagnosis was suggested or apparent. Patients not confirmed by the centers or lost to followup were excluded. In Figure 5 , the clinical features more frequently observed in patients with PFAPA during fever episodes (in red) are compared with patients with other periodic fever syndromes.
Univariate and multivariate analyses were used to identify symptoms for each disease that discriminate independently the disease from the other disorders. 81 A score for each monogenic disease was calculated by summing all the weights associated with the presence or absence of symptoms in each patient. This approach allowed the identification of "positive" and "negative" criteria for each disease, resulting in a high Figure 5 . Prevalence of the clinical manifestations associated with PFAPA in comparison with monogenic forms of periodic fevers. 81 CAPS, Cryopyrin-associated periodic syndromes; MKD, mevalonate kinase deficiency; pts, patients; TRAPS, tumor necrosis factor receptor-associated periodic syndrome.
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WORKSHOP/SYMPOSIUM SUMMARY accuracy observed for each set of criteria. 81 It is conceivable that an evidence-based approach using the comparison of different conditions that enter into differential diagnosis with PFAPA and the combination of "positive" and "negative" criteria could yield the most accurate diagnostic criteria for PFAPA.
Conclusions
PFAPA continues to be an enigma. Future directions in understanding the pathogenesis of PFAPA include evaluation of the efficacy of IL-1 inhibition, validation of biomarkers, investigations of the inflammatory architecture of lymphoid tissue (including the microbiome), and the manner in which variants of hereditary periodic fever syndromes modulate the PFAPA phenotype. The increasingly reported familial susceptibility to PFAPA holds out hope that genetic associations will be found.
Further knowledge of the pathogenesis and genetics of PFAPA will hopefully lead to a laboratory test confirming a PFAPA diagnosis and the development of novel targeted treatments. ■ The First International Conference on Periodic Fever, Aphthous Stomatitis, Pharyngitis, Adenitis Syndrome 
